TARDBP and supranuclear palsy, progressive, 1: For PC1 (functional status), no significant interactions emerged, however, significant main effects of time (Visit 2: t = −2.2; P = 0.025; Visit 3: t = −3.9; P = 0.001) and group for pathological labels of CBD (t = 3.2; P = 0.001), FTLD TDP-43 (t = 2.1; P = 0.03), FTLD-Ubiquitin (t = 2.4; P = 0.01) and PSP (t = 2.2; P = 0.023) were noted.